Glasgow, Scotland, July 12, 2018 (GLOBE NEWSWIRE) -- HCi Viocare (OTCQB:VICA), is pleased to announce that,
further to our Current Report on Form 8-K filed June 15, 2018, HCi Viocare has completed a name change effective July 9, 2018
to Rafina Innovations Inc. Concurrently, the Company completed a reverse split on the basis of 20:1. The
Company will trade under the symbol VICAD for a period of twenty days from effective date, and thereafter, the “D” will be removed
and the symbol will return to “VICA”. During the coming weeks the Company will complete its rebranding with a new logo and updated
corporate website. Our two wholly owned subsidiaries in Glasgow, HCi Viocare Clinics UK Ltd and HCi Viocare Technologies will
continue to operate under their current branding in order to preserve continuity with customers and clients in the UK markets where
they operate.
Sotiris Leontaritis, Rafina Innovations’ CEO and co-founder stated: “It is important that our corporate name
reflect our business objectives. Five years ago, we set out to develop proprietary Medical and Healthcare technologies. Our
revolutionary Flexisense™ technology has found demand for applications in many more industry sectors than we initially anticipated,
and our portfolio of technologies has grown to include a much broader scope of innovations with application across numerous fields,
including many outside the medical technology segment. We feel ‘Rafina Innovations’ better reflects our path forward.
“Adding to our earlier scope of healthcare projects, we are also currently involved with projects related to Human
Augmentation, Automotive safety and Smart Homes. We felt that it was important for our industry partners, our investors and
also for our own in-house technology group, that we project a clear understanding that we are much more than a healthcare
technology company. We are a creative innovation lab with novel technologies under development; technologies which we hope will
affect many aspects of consumers’ everyday lives. We are confident that our improved branding, which will be rolled out in phases
during the coming weeks, will reflect our continuing goal to bring global innovations.”
About Rafina Innovations Inc.
Rafina Innovations operates two wholly owned subsidiaries in Glasgow UK. Firstly, HCi Viocare Technologies, which
is the R&D center where innovative proprietary technologies are being developed for licensing to established industry
participants. And secondly, HCi Viocare Clinics UK, which is the only private Prosthetics and Orthotics clinic in Scotland. This
P&O center is aimed to function as a center of training and excellence for a chain of P&O clinics to be opened, by the
company through joint ventures, in East Mediterranean and the Middle East regions.
Rafina Innovations Inc. is listed on the OTC Markets in the USA, (OTCQB:VICA).
Please visit: www.rafinainnovations.com
www.hci-viocare.co.uk
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks,
uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates",
"believes", "could", and other similar words. All statements addressing product performance, events, or developments that the
Company expects or anticipates will occur in the future are forward-looking statements, including but not limited to future
developments in the areas of athletic shoes and the information and performance of the Company’s technology in such
applications. Because the statements are forward-looking, they should be evaluated in light of important risk factors and
uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States
Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of
the Company's underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In
addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company has acquired its
first operational Prosthetics & Orthotics (P&O) clinic and is continuing development efforts for its other biomedical
technologies, including a “smart insole” and its Flexisense TM sensing technology with several potential applications. There is no
assurance that the Company will be successful in its ongoing expansion and development efforts, or that it will find suitable
commercialization partners for its technologies. Except as required by law, Rafina Innovations disclaims any obligation to update
or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no
assurance that such statements will prove to be accurate and actual results and future events could differ materially from those
anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts
responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents
that Rafina Innovations files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
For further information please contact: For Investors Relations: Sergios Katsaros T:+30 211 0123053 e: sergios.katsaros@rafinainnovations.com
